Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

[Therapy related leukemia]

S Fujisawa¹, A Maruta, R Sakai

¹Department of Hematology/Chemotherapy, Kanagawa Cancer Center.

[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology

|October 1, 1995

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CSPOR-HN02).

Annals of oncology : official journal of the European Society for Medical Oncology·2018

Same author

Dismal outcome of allogeneic hematopoietic stem cell transplantation for relapsed adult T-cell leukemia/lymphoma, a Japanese nation-wide study.

Bone marrow transplantation·2017

Same author

Thymoma-associated multi-organ autoimmunity: two cases and a review of the literature.

Journal of the European Academy of Dermatology and Venereology : JEADV·2017

Same author

Sinusoidal obstruction syndrome after allogeneic hematopoietic stem cell transplantation: Incidence, risk factors and outcomes.

Bone marrow transplantation·2015

Same author

Early application of related SCT might improve clinical outcome in adult T-cell leukemia/lymphoma.

Bone marrow transplantation·2015

Same author

Mode-selective optical packet switching in mode-division multiplexing networks.

Optics express·2015

Therapy-related leukemias (TRL) are difficult to treat, with patients showing poor response to chemotherapy and prognosis. Reduced doses of carcinogenic drugs may be needed to prevent TRL development.

Area of Science:

Hematology
Oncology
Cancer Research

Context:

Therapy-related leukemias (TRL) are secondary malignancies that arise after cancer treatment.
Understanding TRL development and prognosis is crucial for improving patient outcomes.

Purpose:

To analyze the clinical characteristics, treatment, and outcomes of therapy-related leukemias.
To identify potential strategies for preventing TRL.

Summary:

This study identified 11 patients with therapy-related leukemias (TRL) treated between 1983 and 1993.
Patients had a median age of 62 and a history of various primary cancers, including breast cancer and lymphoma.
TRL cases included acute non-lymphoid leukemia, acute lymphoid leukemia, and hypoplastic leukemia.
Ten patients achieved complete remission of their primary tumors before TRL diagnosis.

Related Experiment Videos

Three out of 10 patients receiving anti-leukemic therapy achieved complete remission, with a median survival of 36 days.

TRL patients demonstrated a poor response to chemotherapy and a grim prognosis.

Impact:

The findings suggest that TRL patients have a poor prognosis and limited response to chemotherapy.
The study highlights the need to consider reduced doses of carcinogenic drugs during primary cancer treatment to mitigate TRL risk.